

FORM PTO-1390  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

37522-1006

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/786982

INTERNATIONAL APPLICATION NO.  
PCT/NZ99/00147INTERNATIONAL FILING DATE  
September 3, 1999PRIORITY DATE CLAIMED  
September 3, 1998

## TITLE OF INVENTION

Neuroprotection

## APPLICANT(S) FOR DO/EO/US

Arjan Scheepens et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Petition for revival (PTO/SB/64/PCT), Express Mail EL852463561US

U.S. APPLICATION NO. (if known, see 37 CFR 1.52)  
**09/786982**INTERNATIONAL APPLICATION NO  
PCT/NZ99/00147ATTORNEY'S DOCKET NUMBER  
37522-100621. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO. .... **\$1000.00**International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... **\$860.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$710.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$690.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$100.00****ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS PTO USE ONLY**

\$ 1000

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	29 - 20 =	1	x <b>\$18.00</b>	\$ 162
Independent claims	4 - 3 =	1	x <b>\$80.00</b>	\$ 80

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + **\$270.00**

\$

**TOTAL OF ABOVE CALCULATIONS =**

\$ 1242

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above  
are reduced by 1/2. +

\$

**SUBTOTAL =**

\$

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$

**TOTAL FEES ENCLOSED =**

\$ 1242

Amount to be  
refunded:

\$

charged:

\$

- a. ☒ A check in the amount of \$ 1242 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 08-1641 in the amount of \$ 1242 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 08-1641. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Customer Number 25213

SIGNATURE

Derek P. Freyberg

NAME

29,250

REGISTRATION NUMBER

09/786982

JC02 Rec'd PCT/PTO 1 2 MAR 2001

PATENTS

Attorney Docket No. 37522-1006

EXPRESS MAIL LABEL INFORMATION - 37 CFR 1.10

Express Mail Label No.: EL852463561US

Date of Deposit: March 12, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Arjan Scheepens et al. :

App. No.: (not yet known) : Art Unit: (not yet known)  
Int'l App. No. PCT/NZ99/00147

Filed: (herewith) : Examiner: (not yet known)  
Int'l Filing Date: September 3, 1999

For: Neuroprotection

Box PCT  
Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

Please amend the above-identified application, before  
examination, as follows:

**In the Claims:**

Cancel the word "CLAIMS" and Claims 1-29, and insert  
therefor:

09/786982-0001

-- WE CLAIM:

30. A method for inducing a neuroprotective effect in a brain of a patient, comprising administering growth hormone, an analog thereof, or a functionally equivalent ligand to the brain of the patient.
31. The method of claim 30 where the neuroprotective effect is a neuroprophylactic effect.
32. The method of claim 30 where the neuroprotective effect is a neural rescue effect.
33. The method of claim 32 where the neural rescue effect is the rescue of neurons otherwise destined to die as the result of a prior neuronal insult.
34. A method for inducing a neuroprotective effect in a brain of a patient, comprising causing an increase in the effective concentration of growth hormone or a functionally equivalent endogenous ligand in the brain of the patient.
35. The method of claim 34 where the causing an increase in the effective concentration of growth hormone or ligand comprises direct administration of growth hormone or the ligand.
36. The method of claim 34 where the causing an increase in the effective concentration of growth hormone or ligand comprises administering an agent which either simulates production of growth hormone or the ligand or which lessens or prevents inhibition of growth hormone or ligand activity.
37. The method of claim 34 where the neuroprotective effect is a neuroprophylactic effect.
38. The method of claim 34 where the neuroprotective effect is a neural rescue effect.

09786987-02702

39. The method of claim 38 where the neural rescue effect is the rescue of neurons otherwise destined to die as the result of a prior neuronal insult.
40. A method for inducing a neuroprotective effect in a brain of a patient which comprises causing an increase in the activity of neural growth hormone receptors in the brain of the patient.
41. The method of claim 40 where the causing an increase in the activity of neural growth hormone receptors in the brain of the patient comprises directly administering to the brain of said patient an agent which increases the activity of said neural growth hormone receptors.
42. The method of claim 41 where the agent binds growth hormone receptors.
43. The method of claim 42 where the agent is selected from growth hormone, an analog thereof, prolactin, an analog of prolactin, placental lactogen, and an analog of placental lactogen.
44. The method of claim 41 where the agent effects an increase in the active concentration of an agent which binds neural growth hormone receptors.
45. The method of claim 44 where the agent is selected from growth hormone releasing proteins (GRP), growth hormone releasing hormone (GHRH), functionally equivalent secretagogues of these, and somatotropin release inhibitory factor (SRIF).
46. The method of claim 40 where the neuroprotective effect is a neuroprophylactic effect.

09786987-03702

47. The method of claim 40 where the neuroprotective effect is a neural rescue effect.
48. The method of claim 47 where the neural rescue effect is the rescue of neurons otherwise destined to die as the result of a prior neuronal insult.
49. The method of claim 30 comprising administering growth hormone, an analog thereof, or a functionally equivalent ligand in combination with a secondary neuroprotective agent.
50. The method of claim 49 where the secondary neuroprotective agent is selected from IGF-1, GPE, activin, NGF, TGF- $\beta$ , growth hormone binding proteins, IGF-binding proteins, and bFGF.
51. The method of Claim 49 where the neuroprotective effect is a neural rescue effect to rescue neurons otherwise destined to die as the result of neuronal insult.
52. The method of claim 51 where the neuronal insult is Huntington's disease or Alzheimer's disease, and the secondary neuroprotective agent is at least one of GPE, IGF-1, and activin.
53. The method of claim 51 where the neuronal insult is corticobasal degeneration or Steele-Richardson-Olszewski syndrome, and the secondary neuroprotective agent is IGF-1.
54. The method of claim 51 where the neuronal insult is Devic's disease or Pick's disease, and the secondary neuroprotective agent is at least one of GPE and IGF-1.

55. The method of claim 51 where the neuronal insult is diabetic neuropathy, and the secondary neuroprotective agent is at least one of IGF-1 and activin.
56. A neuroprotective pharmaceutical composition comprising a suitable excipient; growth hormone, an analog thereof, or a functionally equivalent ligand; and a secondary neuroprotective agent, provided that when only one secondary neuroprotective agent is present, it is not IGF-1.
57. The composition of claim 56 where the secondary neuroprotective agent is selected from GPE, activin, NGF, TGF- $\beta$ , growth hormone binding proteins, IGF-binding proteins, and bFGF.
58. The composition of claim 57 which further includes IGF-1. --


#### REMARKS

##### The Amendment

Entry of this amendment is respectfully requested. No new matter is added by the amendments, because the new claims find support in the application as filed. In particular, the new claims are rewritten in more standard US form.

Claims 30-58 are in this application, Claims 1-29 having been canceled, and Claims 30-58 having been added by this amendment. Entry of the amendment and allowance of the claims are requested.

Respectfully submitted,



Derek P. Freyberg  
Attorney for Applicants  
Reg. No. 29,250

Heller Ehrman White & McAuliffe LLP  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
(650) 324-7014  
March 12, 2001  
279285 v01.SV (5ZHX01!.DOC)  
03/12/01 2:12 PM

## NEUROPROTECTION

This invention relates to neuroprotection. In particular, it relates to a new therapeutic use of growth hormone, its analogs and functionally equivalent ligands in neuroprotection.

### BACKGROUND

The presence of growth hormone receptor/binding protein (GHR/BP) has been reported in both the juvenile (Lobie *et al* (1993)) and adult (Burton *et al* (1992)) rat brains, and its pattern of distribution appears to be widespread, especially in the juvenile CNS. The ontogeny of expression of the GHR/BP also appears to be similar to IGF-1 and the IGF-1 receptor expression in the developing CNS, being produced mainly in fetal and early post-natal life and declining thereafter (Bartlett *et al* (1991), Bondy and Lee (1993), Garofalo *et al* (1989)). Studies of transgenic mice have showed that both IGF-1 knockout and growth hormone deficient mice exhibit hypomyelinated, microcephalic brains (Beck *et al* (1995), Noguchi (1991)), thus indicating a role for both growth hormone and IGF-1 in brain growth, development and myelination. A recent study in growth hormone-deficient children has shown a striking correlation between hypothalamic disturbances influencing growth hormone secretion and their relative score in a visual motor psychological test, indicating a link between an abnormal somatotrophic axis and reduced cognitive performance (Andronikof-Sanglade *et al* (1997)).

There has however to date been no demonstration of a neuroprotective function for growth hormone. (By "neuroprotective" is meant exhibiting neuroprophylactic and/or neuronal rescue capabilities in the CNS). While US 4,791,099 does describe the symptoms of central nervous system diseases as being treatable with a combination of growth hormone and androgens, there is no teaching of administering growth hormone alone. Certainly, there is no teaching in US 4,791,099 of growth hormone as having other than an anabolic effect to render patients treated more receptive to the restorative effects of the androgens. No neuroprophylactic or neuronal rescue capabilities are suggested.

It is the applicant's finding that growth hormone is itself neuroprotective. This finding is surprising in spite of the somatotrophic axis relationship between growth



hormone and IGF-1 and the demonstration that IGF-1 has neuronal rescue capabilities, both *in vitro* and *in vivo* (see Knusel *et al* (1990), Guan *et al* (1993)). That is because IGF-1 acts through the IGF-1 receptor whereas growth hormone does not. Thus, growth hormone is neuroprotective in the thalamus, where there is reported distribution of growth hormone receptor immunoreactivity (Lobie *et al* (1993) *Developmental Brain Research* 74: 225) but not in the striatum, whereas IGF-1 is neuroprotective in the striatum, where IGF-1 receptors have been reported to be present (Hill *et al* (1986) *Neuroscience* 17:1127; Lesinak *et al* (1988) *Endocrinology* 123:2089)) but not in the thalamus. Furthermore and as the applicants have found that growth hormone administered centrally to the brain is neuroprotective without effecting a concurrent increase in IGF-1 levels.

It is these surprising findings upon which the present invention is based.

## SUMMARY OF THE INVENTION

In a first aspect, the present invention provides a method for inducing a neuroprotective effect in the brain of a patient which comprises the step of administering growth hormone, an analog thereof or a functionally equivalent ligand to the brain of said patient.

As used herein, "analog" means a fragment or variant of an active agent which has at least substantially equivalent biological activity to that active agent.

The term "functionally equivalent ligand" means an agent which binds to and activates the neural receptors in the brain which growth hormone binds to and activates.

In a further aspect, the invention provides a method for inducing a neuroprotective effect in the brain of a patient which comprises the step of increasing the effective concentration of growth hormone or a functionally equivalent endogenous ligand in the brain of said patient.

Preferably, the effective concentration of said growth hormone/analog/ligand is increased through direct administration.

Alternatively, the effective concentration of growth hormone or ligand is increased through administration of an agent which either stimulates production of growth hormone or the ligand or which lessens or prevents inhibition of growth hormone/ligand activity.

5

Preferably, the neuroprotective effect is a neural rescue effect.

Alternatively, the neuroprotective effect is a neuroprophylactic effect.

10 In a further embodiment, the invention provides a method of treating a patient to rescue neurons otherwise destined to die as the result of a prior neuronal insult which comprises the step of increasing the effective amount of growth hormone, an analog thereof or a functionally equivalent ligand in the brain of said patient.

15 As used herein, "neuronal insult" is used in its broadest possible sense and includes neuronal insults due to trauma (injuries), degenerative diseases and disorders, motor diseases and disorders, demyelinating diseases and disorders, neurological syndromes, eye diseases and sleep disorders.

20 The applicants have found that the neuroprotective role of growth hormone is mediated through the neural growth hormone receptors. By "neural growth hormone receptor" is meant any receptor found in the brain which growth hormone binds to and/or activates or to which growth hormone is capable of binding/activating. Such receptors include growth hormone receptor (GHR) and  
25 prolactin receptor (PRL-R).

Therefore, in a further aspect the invention provides a method for inducing a neuroprotective effect in the brain of a patient which comprises the step of causing an increase in the activity of neural growth hormone receptors in the brain of said  
30 patient.

Preferably, the increase in activity is the result of direct administration to the brain of said patient of an agent which increases the activity of said neural growth hormone receptors.

35

Preferably, said agent is one which binds growth hormone receptors directly. Such an agent can be growth hormone, an analog thereof or a functionally equivalent ligand such as prolactin, an analog of prolactin, placental lactogen or an analog of placental lactogen.

5

Alternatively, the agent is one which effects an increase in the active concentration of an agent which binds neural growth hormone receptors (ie. the agent administered acts indirectly). Preferably, such an agent is selected from growth hormone releasing proteins (GRP), growth hormone releasing hormone (GHRH), functionally equivalent secretagogues of these and somatostatin release inhibitory factor (SRIF).

10

Conveniently, the method is neuroprophylactic.

15

Alternatively, said method induces a neural rescue effect.

In still a further aspect, the invention provides a method of treating a patient to rescue neurons otherwise destined to die as the result of a prior neuronal insult which comprises the step of causing an increase in the activity of neural growth hormone receptors in the brain of said patient.

20

The applicants also contemplate a combination therapy in which growth hormone or an analog/ligand thereof can be administered to rescue a first population of neuronal cells and a second neuroprotective agent can be administered to protect a second population of neuronal cells. The invention therefore further provides a method of treating a patient to protect neurons which comprises administering growth hormone, an analog thereof or a functionally equivalent ligand in combination with an additional neuroprotective agent.

25

Preferably, the additional neuroprotective agent is selected from IGF-1, GPE, activin, NGF, TGF- $\beta$  growth hormone binding proteins, IGF-binding proteins and bFGF.

30

Conveniently, the method induces a neuronal rescue effect to rescue neurons otherwise destined to die as the result of neuronal insult.

35

09786982-002702

In one embodiment, the insult is Huntington's disease or Alzheimer's disease and said growth hormone/analog/ligand is administered in combination with one or more of GPE, IGF-1 and activin.

- 5 In a further embodiment, the insult is corticobasal degeneration or Steele-Richardson-Olszewski syndrome and said growth hormone/analog/ligand is administered in combination with IGF-1.

- 10 In another embodiment, the insult is Devic's disease or Pick's disease and said growth hormone/analog/ligand is administered in combination with one or both of GPE and IGF-1.

- 15 In another embodiment, the insult is diabetic neuropathy and said growth hormone/analog/ligand is administered in combination with one or both of activin and IGF-1.

- 20 In still a further aspect, the invention provides a medicament for use in treating a patient to rescue neurons otherwise destined to die as the result of a prior neuronal insult which comprises, in combination, growth hormone, an analog thereof or a functionally equivalent ligand and one or more selected secondary neuroprotective agents other than IGF-1, preferably one or more of GPE, activin, NGF, TGF- $\beta$ , a growth hormone binding protein, an IGF binding protein and bFGF.

- 25 Preferably, said medicament further includes IGF-1.

- In yet a further aspect, the invention provides the use of growth hormone or an analog thereof or a functionally equivalent ligand in the preparation of a neuroprotective medicament.

- 30 Preferably, said medicament is for use in rescuing neurons otherwise destined to die as the result of neuronal insult.

#### DESCRIPTION OF THE DRAWINGS

- 35 While the present invention is broadly defined above, those persons skilled in the art will appreciate that it is not limited thereto and that it further includes

embodiments of which the following description provides examples. In addition, the invention will be better understood through reference to the accompanying drawings in which:

5 Figure 1 shows the effect of ICV rat growth hormone treatment on serum and CSF IGF-1 levels following moderate HI;

Figure 2 shows the effect of ICV rat growth hormone treatment on neuronal score following moderate HI; and

10

Figure 3 shows the effect of ICV rat growth hormone treatment on neuronal survival following moderate HI.

#### DESCRIPTION OF THE INVENTION

15

As broadly defined above, the present invention relates to neuroprotection. This is both in the sense of neuroprophylaxis and neuronal rescue, with the focus being on rescue.

20

The applicants have found that neuroprotection and in particular neuronal rescue is able to be effected using two approaches. The first approach is through a focus upon growth hormone, its analogs and functionally equivalent ligands. The applicants have found that increasing the effective concentration of growth hormone, its analogs or functionally equivalent ligands within the brain of a patient

25

induces a neuroprotective effect and in particular a neuronal rescue effect.

The growth hormone which is used in this approach can be any mammalian growth hormone, with examples being human growth hormone, rat growth hormone and porcine growth hormone. It is however preferred that the growth hormone employed

30

be human growth hormone where the patient is a human.

The growth hormone which is used in the present invention can be in its substantially purified, native, recombinantly produced, or chemically synthesized forms. For example, the growth hormone can be isolated directly from blood, such

35

as from serum or plasma, by known methods. See, for example, Phillips (1980) *New Eng J. Med* 302:371-380; Svoboda *et al* (1980) *Biochemistry* 19:790-797; Cornell and

Boughdady (1982) *Prep. Biochem.* 12:57; Cornell and Boughdady (1984) *Prep. Biochem.* 14:123; European Patent No. EP 123,228; and US Patent 4,769,361. Alternatively, growth hormone can be synthesized chemically, by any of several techniques that are known to those skilled in the peptide art. See, for example, Li *et al* (1983) *Proc. Natl. Acad. Sci. USA* 80:2216-2220, Stewart and Young (1984) *Solid Phase Peptide Synthesis* (Pierce Chemical Company, Rockford, Illinois, USA) and Barany and Merrifield (1980) *The peptides: Analysis, Synthesis, Biology*, ed. Gross and Meienhofer, Vol 2 (Academic Press, New York, 1980), pp 3-254, for solid phase peptide synthesis techniques; and Bodansky (1984) *Principles of Peptide Synthesis* (Springer-Verlag, Berlin); and Gross and Meienhofer, eds (1980) *The Peptides: Analysis, Synthesis, Biology*, Vol 1 (Academic Press, New York, USA) for classical solution synthesis. Growth hormone can also be chemically prepared by the method of simultaneous multiple peptide synthesis. See, for example, Houghten (1985) *Proc. Natl. Acad. Sci. USA* 82:5131-5135 and US Patent 4,631,211.

Genetic engineering by recombinant DNA techniques can be the most efficient way of producing the growth hormone. The human DNA sequence encoding these proteins is known and can be introduced into host cells for expression. The proteins can be produced by recombinant DNA techniques in *E. coli*, yeast, insect and mammalian cells. A secreted polypeptide can be made by adding a signal sequence to the DNA sequence encoding the neurologic therapeutic. In addition, the DNA sequence can be modulated to make fragments, analogues, or derivatives. Such recombinant DNA techniques are generally available in the art.

Most conveniently, the effective concentration of growth hormone will be increased through direct administration using either growth hormone itself or a growth hormone pro-drug (a form which is cleaved within the body to release growth hormone). It is however not the applicants intention to exclude increasing growth hormone concentration through administration of either growth hormone agonists or secretagogues (substances which effect a direct increase in production of growth hormone within the brain (eg. growth hormone releasing peptides (GHRP) such as GHRP-1, GHRP-2, GHRP-6, Hexarelin, G-7039, G-7502, L-692,429, L-692,585, L-163,191 [Deghenghi *et al.* (1994) *Life Sci.* 54:1321; Bowers (1993) *J. Paed Endocrinol.* 6:21; Smith *et al.* (1993) *Science* 260:1640; McDowell *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92:11165; Patchett *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92:7001; Clark and Robinson (1996) *Cytokine and Growth Factor Reviews* 7(1):65] or growth

hormone releasing hormone (GHRH) [Frohman et al. (1992) *Front Neuroendocrinol.* 13:344; Clark and Robinson (1996) *Cytokine and Growth Factor Reviews* 7(1):65] or inhibitors of growth hormone antagonists (substances which bind growth hormone or otherwise prevent or reduce the action or production of growth hormone within the body). These latter compounds exert an indirect effect on effective growth hormone concentrations through the removal of an inhibitory mechanism, and includes substances such as somatostatin (somatotropin release inhibitory factor (SRIF)) [Gillies (1997) *Trends in Pharmacol. Sci.* 18(3):87].

Another administrable form is a replicable vehicle encoding growth hormone. Such a vehicle (which may be a modified cell line or virus which expresses growth hormone within the patient) has the capability of increasing the concentration of growth hormone within the patient for a prolonged period. [Maxwell et al (1998) *Neurosurgery* 43(5):1157] Such a vehicle can form part of a brain implant.

In addition to growth hormone itself, the use of analogs of growth hormone or functionally equivalent ligands of growth hormone is contemplated.

As used herein, "analog" means a protein or peptoid which is a variant of growth hormone through modification (such as by insertion, deletion or substitution of one or more amino acids, glycosylation, phosphorylation or addition of one or more foreign moieties) but which retains at least substantial functional equivalency.

A protein is a functional equivalent of another protein for a specific function if the equivalent protein is immunologically cross-reactive with, and has at least substantially the same function as, the original protein. The equivalent can be, for example, a fragment of the protein, such as a C-terminal or N-terminal deletion, a fusion of the protein with another protein or carrier, or a fusion of a fragment with additional amino acids. For example, it is possible to substitute amino acids in a sequence with equivalent amino acids using conventional techniques. Groups of amino acids normally held to be equivalent are:

- (a) Ala, Ser, Thr, Pro, Gly;
- (b) Asn, Asp, Glu, Gln;
- (c) His, Arg, Lys;
- (d) Met, Leu, Ile, Val; and

(e) Phe, Tyr, Trp.

Functionally equivalent proteins will generally have at least 70%, preferably at least 80%, more preferably about 90% to 95% or more, and most preferably about 98% or more amino acid sequence identity to the amino acid sequence of the reference molecule. By "reference molecule" is intended a sequence used for comparison which may be either a complete sequence or a subset of the specified sequence. By "sequence identity" is intended the same amino acid residues are found within the variant and the reference molecule when a specified, contiguous segment of the amino acid sequence of the variant is aligned and compared to the amino acid sequence of the reference molecule.

For purposes of optimal alignment of the two sequences, the contiguous segment of the amino acid sequence of the variant may have additional amino acid residues or deleted amino acid residues with respect to the amino acid sequence of the reference molecule. The contiguous segment used for comparison to the reference amino acid sequence will comprise at least twenty (20) contiguous nucleotides, and may be 30, 40, 50, 100 or more nucleotides. Corrections for increased sequence identity associated with inclusion of gaps in the variant's amino acid sequence can be made by assigning gap penalties. Methods of sequence alignment are well known in the art.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (1988) *CABIOS* 4:11-17. Such an algorithm is incorporated into the ALIGN program version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. An additional preferred program is the Pairwise Alignment Program (Sequence Explorer), using default parameters. Another non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al* (1990) *J. Mol. Biol.* 215:403. Nucleotide sequences homologous to the growth



hormone nucleic acid molecules of the invention can be obtained using BLAST nucleotide sequences performed with the NBLAST program, score = 100, wordlength = 12. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to growth hormone protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389. Alternatively, PSI-Blast can be used to perform an iterated search that detects distant relationships between molecules. See Altschul *et al.* (1997) *supra*. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (eg. XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

Functional equivalency of growth hormone analogs can also be readily screened for by reference to the ability of the analog to both bind to and activate the appropriate receptor. In this case, the receptor is a neural growth hormone receptor.

As indicated above, the term "neural growth hormone receptor" is used in this widest possible sense to cover all receptors on neuronal cell populations which growth hormone is capable of binding to and/or activating. Two such receptors are growth hormone receptor (GHR) and prolactin receptor (PRL-R). In particular, the term "neural growth hormone receptor" covers the human GHR and human PRL-R.

The human growth hormone receptor (GHR) is a 620 amino acid single chain protein containing a glycosylated 246 amino acid extracellular ligand binding domain, a single 24 amino acid transmembrane domain and a 350 amino acid cytoplasmic domain (Postel-Vinay and Kelly (1996) *Baillieres Clinical Endocrinology and Metabolism* 10:323). The GHR monomer binds to a single growth hormone (GH) by binding site 1, a second GHR is then required to bind to binding site 2 on the same GH after which the receptor dimerises and signal transduction occurs. Signal transduction involves the activation of cytoplasmic kinases resulting in the phosphorylation of numerous cytoplasmic peptides.

The human prolactin receptor (PRL-R) is a 590 amino acid single chain polypeptide with a glycosylated 210 amino acid extracellular ligand binding domain, a single 24 amino acid transmembrane domain and an intracellular domain of 358 amino acids. The PRL-R monomer binds to a single prolactin (PRL). A second PRL-R is then

required to bind to the same PRL after which the receptor dimerises and signal transduction occurs. Signal transduction involves the activation of cytoplasmic kinases resulting in the phosphorylation of numerous cytoplasmic peptides in a mechanism very similar to the GHR.

5

A second short form of the PRL-R has also been characterised (Kelly *et al* (1991) *Endocrine Reviews* 12:235). This receptor is the same as the long version of the receptor in the extracellular and transmembrane regions but has much smaller cytoplasmic domain of only 57 amino acids.

10

This leads to the applicants second approach to neuroprotection and in particular neuronal rescue. This approach focuses upon neural growth hormone receptors as defined above and upon effecting neuroprotection through the use of agents which both bind to and activate these receptors.

15

It will be appreciated that growth hormone and its analogs are agents which achieve this. Indeed, the use of growth hormone and growth hormone analogs represents a preferred aspect of the invention. However, it should be appreciated that this approach is not restricted to the use of growth hormone and its analogs but also extends to any ligand which fulfils the functional requirement of both binding to and activating (stimulating) the neural growth hormone receptors. Implicit in this will be the ability of the ligand to effect the initiation of intracellular signalling.

20

Examples of such ligands are prolactin and analogs of prolactin and placental lactogen and analogs of placental lactogen. These are also capable of binding to and activating neural growth hormone receptors (Lowman *et al* (1991), *J. Biol. Chem.* 266:10982).

25

Other stimulatory ligands can be identified by a screening protocol employing at least the ligand binding domain of a neural growth hormone receptor. This screening method can, for example, utilise the expression of the neural growth hormone receptor in *Xenopus* oocytes using standard recombinant DNA methods and measurement of the receptor-mediated signal transduction evoked by stimulatory ligands. Further classical "grind and bind" ligand-binding experiments can also be utilised. Here, whole brain or specific brain regions are homogenised and specific-binding of compounds to the neural growth hormone receptor

30

35

09786982-022702

characterised. This technique allows further characterisation of specificity and affinity (potency) of the compound for the receptor complex (Friele *et al* (1989) *Clin. Chem.* 35(5):721-725).

- 5 The methods of the invention have therapeutic effect. By "therapeutic effect" is meant any enhanced survival, proliferation and/or neurite outgrowth of neurons following an insult beyond that which occurs without administration of the therapeutic agent. By "enhanced neuronal survival" is intended that the administration of a therapeutic agent decreases neuronal loss by at least about 1-  
10 10%, preferably about 10%-50%, more preferably about 10%-50%, more preferably about 10%-90%, and most preferably greater than 90% beyond that which occurs without the administration of the agent.

- Methods to quantify the extent of neural damage and to determine if neuronal  
15 survival was enhanced following the administration of a therapeutic agent are well known to those skilled in the art. Such methods include, but are not limited to, histological methods, molecular marker assays, and functional/behaviour analysis. For example, after ischemic injury, there is a significant increase in the density of omega 3 (peripheral-type benzodiazepine) binding sites (Benazodes, J. *et al.* (1990)  
20 *Brain Res.* 522:275-289). Methods to detect omega 3 sites are known and can be used to determine the extent of cerebral ischemia damage. See for example, Gotti, B. *et al* (1990) *Brain Res.* 522:290-307 and references cited therein. Alternatively, Growth Associated Protein-43 (GAP-43) can be used as a marker for new axonal growth following a CNS insult. See, for example, Stroemer *et al* (1995) *Stroke*  
25 26:2135-2144, Vaudano *et al* (1995) *J. Neurosci* 15:3594-3611. The therapeutic effect may also be measured by improved patient motor skills, cognitive function, sensory perception, speech and/or a decrease in the propensity to seizure. Such functional/behaviour tests used to assess sensorimotor and reflex function are described in, for example, Bederson *et al* (1986) *Stroke* 17:472-476, DeRyck *et al*  
30 (1992) *Brain Res* 573:44-60, Markgraf *et al* (1992) *Brain Res.* 575:238-246, Alexis *et al* (1995) *Stroke* 26:2338-2346. Enhancement of neuronal survival may also be measured using the Scandinavian Stroke Scale (SSS) or the Barthel Index.

- For the intended therapeutic application, the active compound (growth hormone,  
35 analog or ligand) will be formulated as a medicament. The details of the formulation will ultimately depend upon the neuroprotective effect to be induced. Where the

neuroprotective effect is a neuronal rescue effect, the formulation will be largely dependent upon the insult to be remedied and the route of administration but will usually include a combination of the active compound with a suitable carrier, vehicle or diluent. Those skilled in the art are familiar with appropriate carriers, vehicles or diluents for each of the commonly employed methods of administration.

To be effective as a neuroprotective agent, a variety of administration routes can be used. Examples include lumbar puncture, intracerebroventricularly (ICV), intraventricular administration involving neurosurgical insertion of a ventricular cannular with an abdominal pump and reservoir and intraparenchymal. In addition, administration of the active compound directed to the CNS may be achieved through the olfactory neural pathway. See, for example, US Patent No. 5,624,898.

Dosage rates will also be formulation- and condition-dependent. However, by way of example, the recommended dosage rate of growth hormone formulated for injection would be in the range of 0.01  $\mu\text{g}/100\text{ g}$  upwards.

The invention, in its various aspects, will now be illustrated by the experimental section which follows. It will however be appreciated that the experiments are non-limiting.

## EXPERIMENTAL

### Materials and Methods

#### *Animal preparation*

The following experimental procedures followed guidelines approved by the University of Auckland Animal Ethics Committee. Weaned 21 day old Wistar rats, weighing between 40 and 50g, were maintained on a 12 hour light and dark cycle and given free access to food and water throughout the study. The rats were paired by sex and weight and randomly assigned to either the treatment or control groups. HI injury was induced using a modified version of the Levine rat preparation as described previously (Sirimanne *et al.*, J Neuroscience Methods, 55: 7-14, 1994). Briefly, the rats were anaesthetised and maintained on a 2% halothane/oxygen mixture and the right carotid artery ligated following exposure through a midventral neck incision. After surgery the rats were allowed to recover for 2 hours in a

carefully controlled environment of 34°C with 85±5% relative humidity. They were then exposed to 15 minute hypoxia (8% oxygen in nitrogen).

#### *Treatment*

5 Commencing 2 hours after the end of hypoxia, rats in the treatment group (n=12) received 20µg recombinant rat growth hormone in a 10µl infusion, the control group received vehicle only. The infusion procedure was performed under heat lamps to prevent the animals from cooling. All solutions and needles were prepared and kept  
10 under aseptic conditions.

The rats were lightly anaesthetized again using 0.15ml Saffan™ (Pitman-Moore Ltd, NZ). The infusion was made into the right lateral cerebral ventricle guided by a metal cap fitted over the rat head using a modified technique originally described by  
15 Jirikowski (J Neuroscience Methods, 42: 115-118, 1992), in order to ensure correct placement of the infusion needle. Recombinant rat growth hormone (2mg/ml in 8.77mg/ml NaCl, 2.5mg/ml phenol, 2.0mg/ml polysorbate 20 and 10mM sodium citrate pH 6.0) or vehicle only was administered in a single dose at a rate of 1.0µl /minute controlled by a calibrated microinfusion pump. The infusion needles were  
20 left in place a further 3 minutes to prevent backflow.

#### *CSF sampling*

Three days after hypoxia cerebrospinal fluid (CSF) samples were taken. The rats were anaesthetised under Saffan anaesthesia and maintained on 2% halothane.  
25 They were then placed in a stereotaxic frame with the head flexed forward to allow blunt dissection of the muscle over the cisterna magna in order to expose the dura. A fine 30 gauge needle was then used to extract CSF with the aid of a binocular magnifier. The rats were euthanised by an overdose of sodium pentobarbitol administered ip and blood samples taken directly from the heart.

30

#### *Histology*

Brains were collected for histological processing after *in situ* fixation by transcardial perfusion with saline followed by a freshly prepared modified Bouin's solution (0.1M PBS, 4% paraformaldehyde [w/v], 0.08% glutaraldehyde [v/v], 15% picric acid [v/v  
35 of saturated solution]). Brains were removed, weighed and left in modified Bouin's solution overnight at room temperature. The following day the brains were placed in 70% ethanol for 3-4 days. The ethanol was replaced with fresh solution daily.

The brains were then processed for paraffin embedding (dehydration through a graded series of ethanols, delipidation in chloroform, infiltration with paraffin wax, blocking in paraffin wax). Eight  $\mu\text{m}$  sections were cut from the tissue and placed on to poly-L-lysine pre-coated slides. Sections were stained using acid-fuschin/thionin.

#### *Neuronal scoring procedure*

Neural outcome was assessed using two levels in each brain; at the mid level of the striatum (Bregma + 0.8mm) and at the mid level of the dorsal horn of the hippocampus (Bregma -3.3). Neuronal outcome was assessed using two techniques:

##### 1) Scoring in the cortex and hippocampus:

The frontoparietal cortex and the hippocampus were assessed by a blinded assessor for neuronal score using a standard five point neuronal loss score (Williams et al., Pediatric Research, 27: 561-565, 1990): 4= no damage, 3 = 0-10% cell loss, 2 = 11 to 50% cell loss, 1=51-90% cell loss, 0= >90% cell loss.

The cortex was scored at the level of the striatum (Bregma +8.0mm) and at the level of the dorsal horn of the hippocampus (Bregma -3.3) and was divided into 5 regions. The hippocampus was scored in the CA1/2, CA3 and dentate gyrus separately. The neuronal scores were then combined for each structure and compared between treatment groups.

##### 2) Scoring in the striatum and thalamus:

Four regions each of the striatum and thalamus were scored using an ocular micrometer on a light microscope at 200x magnification. Each region was counted using 4 grids of the micrometer at  $200\mu\text{m}^2/\text{grid}$ . Healthy neurons were counted in identical regions in the injured and contralateral hemisphere of each brain and % survival was calculated according to the following: counts RHS/counts LHS x 100 for each region. The survival scores relating to each structure were then combined and compared between the treatment and control groups.

#### *Radioimmunoassay for IGF-1 in plasma and CSF*

IGF-1 in blood plasma and CSF were measured using an IGF binding protein (IGFBP) blocked radioimmunoassay (RIA) first described by Blum and Breier (Growth Regulation, 4: 11-19, [1994]). A polyclonal antibody (#878/4) raised in New Zealand

white rabbits which has a very high affinity and specificity for IGF-1 and low cross-reactivity with IGF-II (0.01%) was used. This assay utilises a non-extraction process with samples diluted in acidic buffer and co-incubated with an excess of IGF-II. Dilution at pH 2.8 followed by addition of IGF-II serves to functionally block binding protein interference.

Plasma was diluted (1:200-1:400) in acidic buffer (20mM sodium phosphate pH 2.8, 0.1mM NaCl, 0.1% BSA, 0.02% NaN<sub>3</sub>, 0.1% triton X-100) and CSF samples were diluted (1:11) in 0.5M sodium phosphate, 1% BSA, 1% triton X-100, 0.1% NaN<sub>3</sub>, 1mM PMSF, pH 1.25 in order to dissociate IGFs from IGFbps. The primary antibody, with IGF-II in excess at 25ng/tube, was diluted in a buffer that re-neutralised the pH (100mM sodium phosphate [pH7.8], 40mM NaCl, 0.02% NaN<sub>3</sub>, 0.2% BSA, 0.1% triton X-100) to an initial working dilution of 1:50000. 0.1ml of diluted sample, control, or standard (rh-IGF-1, Genentech, San Fransisco) was incubated with 0.1ml of antibody-IGF-II solution and 0.1ml <sup>125</sup>I-IGF-1 at 15-20000 counts per tube. After incubation for 48 hours at 4°C, 1ml of the secondary antibody complex was added and tubes incubated for a further 1 hour at room temperature. Following centrifugation at 3800rpm/30min at 4°C, tubes were decanted and the pellet counted by gamma counter.

Iodination of rh-IGF-I was performed using a modification of the Chloramine-T method of Hunter and Greenwood (Biochemical Journal, 91: 43-56, 1964). The validation of this assay system was performed according to the recommendations of the Third International Symposium on Insulin-Like Growth Factors (Bang *et al.*, Endocrinology, 136: 816-81, [1995]) including parallel displacement to the standard curve of CSF and recoveries of cold IGF-I. Recovery of unlabelled IGF-I in CSF was 89.6% (n=2). The ED-50 was 0.1ng/tube and the intra- and inter-assay coefficients of variation were 5% and 9% respectively.

### Statistics

The data was analysed using paired t-tests or the non-parametric equivalent, Wilcoxon signed rank test. Calculations were performed using Sigmastat™ v2.0 (Jandel Scientific, San Rafael, California). All results are expressed as mean ± sem.

### Results

The results are shown in Figures 1-3.

Growth hormone treatment had no effect on brain weight compared to vehicle only treated animals at post mortem ( $1.432 \pm 0.032$  vs  $1.455 \pm 0.028$ g).

- 5 Growth hormone treatment caused a trend towards a reduction in the fall in serum IGF-1 caused by the HI injury ( $159 \pm 7.3$  vs  $135.8 \pm 11.7$ ng/ml,  $p=0.068$ ). CSF IGF-1 levels were much lower than those in plasma. CSF IGF-1 levels were unchanged by the growth hormone treatment ( $3.82 \pm 0.35$  vs  $3.86 \pm 0.27$ ng/ml). This can be seen in Figure 1.

10

Cortical neuronal score was significantly improved by growth hormone treatment. The combined score for all five cortical regions at the levels of the striatum and hippocampus was ( $3.54 \pm 0.074$  vs  $2.98 \pm 0.124$ ,  $p<0.001$ ). This is shown in Figure 2.

- 15 Hippocampal neuronal score was significantly improved by growth hormone treatment. The combined score for CA1/2, CA3 and the dentate gyrus was ( $3.03 \pm 0.176$  vs  $1.818 \pm 0.259$ ,  $p=0.005$ ). This is shown in Figure 2.

- 20 The neuronal survival score for the dorsolateral thalamus was significantly improved by growth hormone treatment. The combined score of the four areas counted and compared to the contralateral hemisphere was ( $104 \pm 2.18$  vs  $87.4 \pm 4.67\%$ ,  $p=0.006$ ). This is shown in Figure 3.

- 25 The neuronal survival score for the dorsolateral striatum was not significantly improved by the growth hormone treatment. The combined score of the four areas counted and compared to the contralateral hemisphere was ( $83.8 \pm 4.7$  vs  $75.3 \pm 6.1\%$ ,  $p=0.178$ ). This is shown in Figure 3.

### Conclusions

- 30 Growth hormone administered centrally is effective as a neuronal rescue agent. The neuronal rescue effect occurred without a concurrent increase in CSF-IGF-1, demonstrating the neuroprotective effect is independent of IGF-1.

- 35 Growth hormone is effective as a neuronal rescue agent in regions of the brain where the endogenous growth hormone receptor is expressed (cortex, hippocampus



and thalamus) and not in areas where it is not (striatum). This indicates that the neuroprotective effect of GH is operating via either the growth hormone receptor or the prolactin receptor.

5

## **INDUSTRIAL APPLICATION**

The invention therefore provides new approaches to neuroprotection. In particular, it provides new approaches to neuronal rescue.

10

The approaches of the invention have application in both therapy and prophylaxis. In particular, they have application in the treatment of patients who have suffered neuronal insult, including by injury, degenerative diseases and disorders, motor diseases and disorders, demyelinating diseases and disorders, neurological syndromes, eye diseases and sleep disorders. Specifically contemplated are the following:

15

### **Injury**

Stroke, traumatic brain injury, asphyxia, spinal injuries and CO toxicity.

20

### **Degenerative Diseases and Disorders**

Familial and non-familial Alzheimer's disease, multi-infarct dementia, frontal lobe dementia of the non-Alzheimer-type, Pick's disease, Huntington's disease, Werdnig Hoffmann disease, Wernicke's encephalopathy, Ataxia-telangiectasia, Corticobasal degeneration, Down's syndrome, Rett syndrome, IUGR, Alper's disease, Steele-Richardson-Olszewski syndrome, temporal lobe epilepsy, status epilepticus and undefined mental retardation.

25

### **Motor diseases and disorders**

Spinocerebellar ataxia, progressive myoclonic ataxic syndrome, Leigh's disease, multiple system atrophy, the cerebral palsies, Friedreich's ataxia, pure hereditary spastic paraplegia, spinal muscular atrophies, diabetic neuropathy, hereditary sensory neuropathy type I, ALS, chronic idiopathic ataxic neuropathy, Tangier disease.

35

09786982-022702

**Demyelinating diseases and disorders**

Inflammatory involvement: acute disseminated encephalomyelitis, optic neuritis, transverse myelitis, Devic's disease, the leucodystrophies, Multiple Sclerosis; Non-inflammatory involvement: Progressive multifocal leucoencephalopathy, central pontine myelinolysis.

**Neurological syndromes**

Foetal alcohol syndrome, Autism and Myoclonic ataxia.

10 **Eye diseases**

Glaucoma

**Sleep Disorders**

Narcolepsy

15

Further, while the growth hormone/growth hormone receptor approach of the invention can be employed alone in the above therapies, it is also contemplated that a combination therapy approach can be taken. This latter approach involves administering, in particular, growth hormone or an analog/ligand thereof in combination with a secondary neuroprotective agent. This secondary neuroprotective agent will generally be protective, at least in part, of a population neuronal cells which is distinct from the population of neuronal cells which are protected by growth hormone and its analogs/ligands.

20

25 Secondary neuroprotective agents may be selected from, but not limited to, the group comprising growth factors. By "growth factors" is meant an extracellular polypeptide-signaling molecule that stimulates a cell to grow or proliferate. Preferred growth factors are those to which a broad range of cell types respond. Examples of neurotrophic growth factors include, but are not limited to, fibroblast growth factor family members such as basic fibroblast growth factor (bFGF) (Abraham *et al* (1986) *Science* 233:545-48), acidic fibroblast growth factor (aFGF) (Jaye *et al* (1986) *Science* 233:541-45), the hst/Kfgf gene product, FGF-3 (Dickson *et al* (1987) *Nature* 326-833), FGF-4 (Zhan *et al* (1988) *Mol. Cell. Biol.* 8:3487-3495), FGF-6 (deLapeyriere *et al* 1990) *Oncogene* 5:823-831), Keratinocyte growth factor (KGF) (Finch *et al* (1989) *Science* 245:752-755) and androgen-induced growth factor (AIGF) (Tanaka *et al* (1992) *Proc. Natl. Acad. Sci USA* 89:8928-8923). Additional

35

09786987-0220-23698/60

members of the FGF family include, for example, int-2, fibroblast growth factor homologous factor-1 (FHF-1) (US Patent No. 5,872,226), FHF-2 (US Patent No. 5,876,697), FHF-3 and FHF-4 (Smallwood *et al* (1996) *Proc. Natl. Acad. Sci. USA* 93:9850-9857), keratinocyte growth factor 2 (Emoto *et al* (1997) *J. Biol Chem* 272:23191-23194), glia-activating factor (Miyamoto *et al* (1993) *Mol. Cell Biol.* 13:4251-4259), FGF-18 (Hu *et al* (1998) *Mol Cell Biol* 18:6063-6074), and FGF-16 (Miyake *et al* (1988) *Biochem. Biophys. Res. Commun* 243:148-152).

Additional secondary neuroprotective agents include ciliary neurotrophic factor (CNTF), nerve growth factor (NGF) (Seiler, M. (1984) *Brain Research* 300:33-39; Hagg T, *et al* (1988) *Exp Neurol* 101:303-312; Kromer L F (1987) *Science* 235:214-216; and Hagg T *et al* (1990) *J. Neurosci* 10(9):3087-3092), brain derived neurotrophic factor (BDNF) (Kiprianova, I *et al* (1999) *J. Neurosci. Res.* 56:21-27), Neurotrophin 3 (NT3), Neurotrophin 4 (NT4), transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) (Henrick-Noack, P *et al* (1996) *Stroke* 27:1609-14), bone morphogenic protein (BMP-2) (Hattori, A *et al.* (1999) *J. Neurochem* 72:2264-71), glial-cell line derived neurotrophic factor (GDNF) (Miyazaki, H *et al* (1999) *Neuroscience* 89:643-7), activity-dependent neurotrophic factor (ADNF) (Zamostiano, R *et al* (1999) *Neurosci Letter* 264:9-12), cytokine leukemia inhibiting factor (LIF) (Blesch, A *et al* (1999) *J. Neurosci.* 19:3356-66), oncostatin M, interleukin, and the insulin-like growth factors 1 and 2.

Other forms of secondary neuroprotective agents include, for example, clomethiazole (Zendra) (Marshall, J W *et al* (1999) *Exp Neurol* 156:121-9); kynurenic acid (KYNA) (Salvati, P *et al* (1999) *Prog. Neuropsychopharmacol Biol Psychiatry* 23:741-52), Semax (Miasoedova, N. F. *et al* (1999) *Zh Nevrol Psikiatr Imss Korsakova* 99:15-19), FK506 (tacrolimus) (Gold, B G *et al* (1999) *J. Pharmacol. Exp. Ther.* 289:1202-10), L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (Inokuchi, J. *et al* (1998) *Act Biochim Pol* 45:479-92), adrenocorticotropin-(4-9) analogue (ORG 2766) and dizolcipine (MK-801) (Herz, R C *et al* (1998) *Eur. J. Pharmacol* 346:159-65), cerebral interleukin-6 (Loddick, S A *et al* (1998), *J. Cereb Blood Flow Metab* 18:176-9), selegiline (Semkova, I *et al* (1996) *Eur. J. Pharmacol* 315:19-30), MK-801 (Barth, A *et al* (1996), *Neuro Report* 7:1461-4; glutamate antagonists such as, NPS1506, GV1505260, MK801 (Baumgartner, W A *et al* (1999) *Ann Thorac Surg* 67:1871-3), GV150526 (Dyker, A G *et al* (1999) *Stroke* 30:986-92); AMPA antagonists such as NBQX (Baumgartner, W A (1999) *et al. Ann Thora Surg* 67:1871-3, PD152247 (PNQX) (Schielke, G P *et al* (1999) *Stroke* 30:1472-7), SPD 502

(Nielsen, E O *et al* (1999) *J. Pharmacol Exp Ther* 289:1492-501), LY303070 and LY300164 (May, PC *et al* (1999) *Neuroscience Lett* 262:219-221).

In one embodiment, the secondary neuroprotective agent is IGF-1 and/or a biologically active variant of IGF-1. IGF-1 is a 70 amino acid neurotrophic polypeptide hormone that is widely distributed in the central nervous system and exhibits both insulin-like and mitogenic growth biological activities (Baskin, D G *et al* (1988) *Trends in Neuroscience* 11:107-111). *In vitro* studies have demonstrated that the neuroprotective effects of IGF-1 extend to several types of neurons in the CNS (Knusel *et al* (1990) *J. Neurosci.* 10:558-570, Svezic and Schubert (1990) *Biochem. Biophys. Res. Commun.* 172:54-60 McMorris and Dubois (1988), *J. Neurosci Res.* 21:199-209). In addition, *in vivo* studies using various experimental animal models have shown exogenous administration of IGF-1 soon after a CNS insult elicits a neuroprotective effect (Guan *et al* (1993) *J. Cereb Blood Flow Metab* 13:609-616 and Johnston *et al* (1996) *J. Clin. Invest.* 97:300-308, US Patent No. 5,861,373, US Patent No. 5,093,317, US Patent No. 5,093,317, US Patent No. 5,776,897 and references cited therein.

Preferred secondary neuroprotective agents include IGF-1, GPE, activin, NGF, TGF- $\beta$  growth hormone binding protein, IGF-binding proteins (especially IGFBP-3), and bFGF.

Specific combinations include growth hormone and one or more of GPE, IGF-1 and activin for use in the therapy of Huntington's disease or Alzheimer's disease; growth hormone and IGF-1 for use in the therapy of corticobasal degeneration or Steele-Richardson-Olszewski syndrome; growth hormone and one or both of GPE and IGF-1 for use in the therapy of Devic's disease or Picks disease; and growth hormone and one or both of activin and IGF-1 for use in the therapy of diabetic neuropathy.

Where the combination therapy approach is viewed as desirable, the respective active agents can be formulated for co-administration, including as a single medicament. The invention therefore provides such neuroprotective medicaments which comprise, in combination, growth hormone or an analog thereof together with one or more of the secondary neuroprotective agents above other than IGF-1, particularly one or more of GPE, activin, NGF, TGF- $\beta$  and bFGF. Where desirable, such medicaments can further include IGF-1.

Such medicaments can be prepared in any conventional manner, and can again include standard pharmaceutically-acceptable vehicles, carriers or diluents.

- 5 Those persons skilled in the art will appreciate that the above description is provided by way of example only.

## REFERENCES

10

Andronikof-Sanglade, A., Fjellestad-Paulsen, A., Ricard-Malivoir, S., and Evain-Brion, D. (1997). Specific abnormalities in a visual motor psychological test in short children with abnormal growth hormone secretion. *Acta Paediatrica* **86**[2], 154-159.

15

Bartlett, W.P., Li, X.S., Williams, M., and Benkovic, S. (1991). Localisation of insulin-like growth factor-1 mRNA in murine central nervous system during postnatal development. *Developmental Biology* **147**, 239-250.

20

Beck, K.D., Powellbraxton, L., Widmer, H.R., Valverde, J. and Hefti, F. (1995). IGF-1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. *Neuron* **14**, 717-730.

25

Bondy, C. and Lee, W.H. (1993) Correlation between insulin-like growth factor (IGF) binding protein-5 and IGF-1 gene expression during brain development. *Journal of Neuroscience* **13**, 5092-5104.

30

Burton, K.A. Kabigting, E.B., Clifton, D.K. and Steiner, R.A. (1992). Growth hormone receptor messenger ribonucleic acid distribution in the adult male rat brain and its colocalisation in hypothalamic somatostatin neurons. *Endocrinology* **131**, 958-963.

35

Garofalo, R.S. and Rosen, O.M. (1989). Insulin and insulin-like growth factor 1 (IGF-1) receptors during central nervous system development: expression of two immunologically distinct IGF-1 receptor beta subunits. *Molecular & Cellular Biology* **9**, 2806-2817.

Lobie, P.E., Garcia Aragon, J., Lincoln, D.T., Barnard, R., Wilcox, J.N., and Waters, M.J. (1993). Localisation and ontogeny of growth hormone receptor gene expression in the central nervous system. *Developmental Brain Research* **74**[2], 225-233.

5

Noguchi, T. (1991). Retarded cerebral growth of hormone-deficient mice. *Comparative Biochemistry & Physiology - C: Comparative Pharmacology & Toxicology* **98**[1], 239-248.

10 Clark, R.G. and Robinson, I.C.A.F. (1996). Up and Down the Growth Hormone Cascade. *Cytokine and Growth Factor Reviews* Vol 7, No. 1 pp 65-80.

Bowers, C.Y.(1993). GH releasing peptides-structure and kinetics. *J. Paed. Endocrinology*, **6**:21-31.

15

Clark, R.G., Robinson, I.C.A.F. (1996). Up and down the growth hormone cascade. *Cytokine and Growth Factor Reviews* **75**(1), 65-80.

20 Deghenghi, R., Cananzi, M.M., Torsello, A., Battisti, C., Muller, E.E., Locatelli, V. (1994). GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. *Life Sci.* **54**, 1321-1328.

Frielle, T. Caron, M.G., Leftowitz, R.J. (1989). Properties of the beta 1-and beta 2-adrenergic receptor subtypes revealed by molecular cloning. *Clinical Chemistry* **35**(5): 721-5.

25

Frohman, L.A., Downs, T.R., Chomczynski, P. (1992). Regulation of growth-hormone secretion. *Front Neuroendocrinol* **13**, 344-405.

30 Gillies, G. (1997). Somatostatin: the neuroendocrine story. *Trends in Pharmacological Science* **18**(3), 87-95.

Kelly, P.A., Dijane, J., Postel-Vinay, M-C., Ederly, M. (1991). The prolactin/growth hormone receptor family **12**(3), 235-251.

35

Lowman, H.B., Cunningham, B.C., Wells, J.A. (1991). Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen. *Journal of Biological Chemistry* **266**, 10982-10988.

- 5 Maxwell, M., Allegra, C., MacGillivray, J., Hsu, D.W., Hedley-Whyte, E.T., Riskind, P., Madsen, J.R., Black, P.M. (1998). Functional transplantation of the rat pituitary gland. *Neurosurgery* **43**(5), 1157-1163.

- 10 McDowell, R.S., Elias, K.A., Stanley, M.S., et al. (1995). Growth hormone secretagogues: characterization, efficacy and minimal bioactive conformation. *Proc. Natl. Acad. Sci. USA* **92**, 11165-11169.

- 15 Patchett, A.A., Nargund, R.P., Tata, J.R. et al. (1995). Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. *Proc. Natl. Acad. Sci. USA* **92**, 7001-7005.

Postel-Vinay, M-C., and Kelly, P.A. (1996). Growth hormone receptor signalling. *Baillieres Clinical Endocrinology and Metabolism* **10**, 323-336.

- 20 Guan et al (1993) *J. Cereb. Blood Flow Metab.* 13:609-616.

Knusel et al (1990) *J. Neurosci.* 10:558-570.

09786982-02270

**CLAIMS**

1. A method for inducing a neuroprotective effect in the brain of a patient which comprises the step of administering growth hormone, an analog thereof or a functionally equivalent ligand to the brain of said patient.
- 5 2. A method for inducing a neuroprotective effect in the brain of a patient which comprises the step of increasing the effective concentration of growth hormone or a functionally equivalent endogenous ligand in the brain of said patient.
3. A method as claimed in claim 2 wherein the effective concentration of said  
10 growth hormone or ligand is increased through direct administration.
4. A method as claimed in claim 2 wherein the effective concentration of growth hormone or ligand is increased through administration of an agent which either stimulates production of growth hormone or the ligand or which lessens or prevents inhibition of growth hormone or ligand activity.
- 15 5. A method as claimed in any one of claims 1 to 4 wherein the neuroprotective effect is a neural rescue effect.
6. A method as claimed in any one of claims 1 to 4 wherein the neuroprotective effect is a neuroprophylactic effect.
7. A method of treating a patient to rescue neurons otherwise destined to die  
20 as the result of a prior neuronal insult which comprises the step of increasing the effective amount of growth hormone, an analog thereof or a functionally equivalent ligand in the brain of said patient.
8. A method for inducing a neuroprotective effect in the brain of a patient which comprises the step of causing an increase in the activity of neural  
25 growth hormone receptors in the brain of said patient.
9. A method as claimed in claim 8 wherein the increase in activity is the result of direct administration to the brain of said patient of an agent which increases the activity of said neural growth hormone receptors.
10. A method as claimed in claim 9 wherein said agent is one which binds  
30 growth hormone receptors.



11. A method as claimed in claim 10 wherein said agent is selected from growth hormone, an analog thereof, prolactin, an analog of prolactin, placental lactogen or an analog of placental lactogen.
- 5 12. A method as claimed in claim 9 wherein said agent is one which effects an increase in the active concentration of an agent which binds neural growth hormone receptors.
- 10 13. A method as claimed in claim 12 wherein said agent is selected from growth hormone releasing proteins (GRP), growth hormone releasing hormone (GHRH), functionally equivalent secretagogues of these and somatotropin release inhibitory factor (SRIF).
14. A method as claimed in any one of claims 8 to 13 which is neuroprophylactic.
15. A method as claimed in any one of claims 8 to 13 which induces a neural rescue effect.
- 15 16. A method of treating a patient to rescue neurons otherwise destined to die as the result of a prior neuronal insult which comprises the step of causing an increase in the activity of neural growth hormone receptors in the brain of said patient.
- 20 17. A method of treating a patient to protect neurons which comprises administering growth hormone, an analog thereof or a functionally equivalent ligand in combination with a secondary neuroprotective agent.
18. A method as claimed in claim 17 wherein said secondary neuroprotective agent is selected from IGF-1, GPE, activin, NGF, TGF- $\beta$  growth hormone binding proteins, IGF-binding proteins and bFGF.
- 25 19. A method as claimed in claim 17 which induces a neuronal rescue effect to rescue neurons otherwise destined to die as the result of neuronal insult.
20. A method as claimed in claim 19 in which the insult is Huntington's disease or Alzheimer's disease and said growth hormone, analog or ligand is administered in combination with one or more of GPE, IGF-1 and activin.

21. A method as claimed in claim 19 in which the insult is corticobasal degeneration or Steele-Richardson-Olszewski syndrome and said growth hormone, analog or ligand is administered in combination with IGF-1.
- 5 22. A method as claimed in claim 19 in which the insult is Devic's disease or Pick's disease and said growth hormone, analog or ligand is administered in combination with one or both of GPE and IGF-1.
23. A method as claimed in claim 19 in which the insult is diabetic neuropathy and said growth hormone, analog or ligand is administered in combination with one or both of activin and IGF-1.
- 10 24. A medicament for use in treating a patient to rescue neurons otherwise destined to die as the result of a prior neuronal insult which comprises, in combination, growth hormone, an analog thereof or a functionally equivalent ligand and one or more selected secondary neuroprotective agents, with the proviso that when one secondary neuroprotective agent is present, it is not IGF-1.
- 15 25. A medicament as claimed in claim 24 in which one or more of GPE, activin, NGF, TGF- $\beta$ , a growth hormone binding protein, an IGF binding protein and bFGF.
26. A medicament as claimed in claim 25 which further includes IGF-1.
- 20 27. The use of growth hormone or an analog thereof or a functionally equivalent ligand in the preparation of a neuroprotective medicament.
28. The use of claim 27 wherein said medicament is for rescuing neurons otherwise destined to die as the result of neuronal insult.
- 25 29. The use of claim 27 wherein said medicament further comprises one or more selected secondary neuroprotective agents, provided that when one secondary neuroprotective agent is present, it is not IGF-1.

FIGURE 1

Effect of ICV rat GH treatment on serum and CSF IGF-1 levels following moderate HI




FIGURE 2

Effect of ICV rat GH treatment on neuronal score following moderate HI





FIGURE 3

Effect of ICV rat GH treatment on neuronal survival following moderate HI



#2

<b>PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)</b>	Docket Number (Optional) 37522-1006
---	--

First named inventor: Arjan Scheepens  
International (PCT) Application No.: PCT/NZ99/00174 U.S. Application No.:  
(if known)  
Filed: September 3, 1999  
Title: Neuroprotection

Attention: PCT Legal Staff  
Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

12 APR 2001

**Legal Staff  
International Division**

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.494(b) or (c) or 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.494(g) or 1.495(h).

**APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION**

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee--required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

**1. Petition fee**

☐ Small entity - fee \$ \_\_\_\_\_ (37 CFR 1.17(m)). Applicant claims small entity status.  
See 37 CFR 1.27.

☒ Other than small entity - fee \$ 1240 (37 CFR 1.17(m))

**2. Proper reply**

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s) in the form of  
Transmittal (Form PTO-1390) and fee (identify type of reply):

- ☐ has been filed previously on \_\_\_\_\_  
☒ is enclosed herewith.

03/15/2001 NGUYEN 00000137 09786982

04 FC:141

1240.00 OP

[Page 1 of 2]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

- ☒ Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.
- ☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$\_\_\_\_\_ for a small entity or \$\_\_\_\_\_ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

March 12, 2001  
Date

Telephone  
Number: (650) 324-7014

  
Signature

Derek P. Freyberg, Reg. No. 29,250

Typed or printed name

Heller Ehrman White & McAuliffe LLP

Address

275 Middlefield Road

Menlo Park CA 94025-3506

- Enclosures: ☒ Response  
☒ Fee Payment  
☐ Terminal Disclaimer Form  
☐ \_\_\_\_\_

Express Mail EL852463561US

## DECLARATION

Attorney Docket No.  
37522-1006

18 USC 1001 and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

FIRST JOINT INVENTOR INVENTOR'S SIGNATURE DATE

Arjan Scheepens



10/12/01

RESIDENCE

Maastricht, Nederland

NLX

CITIZENSHIP

Nederland/New Zealand

MAILING ADDRESS

Batterijstraat 66A, 6211-SJ Maastricht, Nederland

SECOND JOINT INVENTOR

INVENTOR'S SIGNATURE

DATE

Christopher E. Williams

RESIDENCE

Auckland, New Zealand

CITIZENSHIP

New Zealand

MAILING ADDRESS

2/73b Carlton Gore Road, Grafton, Auckland, New Zealand

THIRD JOINT INVENTOR

INVENTOR'S SIGNATURE

DATE

PETER DAVID GLUCKMAN

RESIDENCE

Auckland, New Zealand

CITIZENSHIP

New Zealand

MAILING ADDRESS

78 Lucerne Road, Remuera, Auckland 5, New Zealand

FOURTH JOINT INVENTOR

INVENTOR'S SIGNATURE

DATE

ROSS GRAHAM CLARK

RESIDENCE

Auckland, New Zealand

CITIZENSHIP

New Zealand

MAILING ADDRESS

25 Glen Road, Devonport, Auckland, New Zealand



As a below named joint inventor, each of us hereby declares as follows:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am an original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NEUROPROTECTION

the specification of which was filed in the US Patent & Trademark Office on March 12, 2001 as Application No. 09/786,982, being a 371 of PCT/NZ99/00147, filed on September 3, 1999.

I state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information of which I am aware that is material to the examination of this application in accordance with 37 CFR 1.56.

I hereby claim the priority under 35 USC 119(a-d) or 365(c) of New Zealand Application No. 331719, filed September 3, 1998.

Address all written correspondence to:  
Customer Number 25213.

Direct all telephone calls to:  
Derek P. Freyberg, at (650) 324-7014.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under

## DECLARATION

Attorney Docket No.  
37522-1006

18 USC 1001 and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

FIRST JOINT INVENTOR INVENTOR'S SIGNATURE DATE

Arjan Scheepens

RESIDENCE CITIZENSHIP  
Maastricht, Nederland Nederland/New Zealand

MAILING ADDRESS  
Batterijstraat 66A, 6211-SJ Maastricht, Nederland

SECOND JOINT INVENTOR INVENTOR'S SIGNATURE DATE  
2-01  
Christopher E. Williams C. Williams 22 Jan 2002

RESIDENCE CITIZENSHIP  
Auckland, New Zealand New Zealand

MAILING ADDRESS NZX  
2/73b Carlton Gore Road, Grafton, Auckland, New Zealand

THIRD JOINT INVENTOR INVENTOR'S SIGNATURE DATE  
3-01  
PETER DAVID GLUCKMAN Peter David Gluckman

RESIDENCE CITIZENSHIP  
Auckland, New Zealand New Zealand

MAILING ADDRESS NZX  
78 Lucerne Road, Remuera, Auckland 5, New Zealand

FOURTH JOINT INVENTOR INVENTOR'S SIGNATURE DATE  
4-01  
ROSS GRAHAM CLARK Ross Clark 29 Jan '02

RESIDENCE CITIZENSHIP  
Auckland, New Zealand New Zealand

MAILING ADDRESS NZX  
25 Glen Road, Devonport, Auckland, New Zealand